Volume 6.45 | Nov 20

Cord Blood News 6.45 November 20, 2014
Cord Blood News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CBN on Twitter
Hematopoietic Stem/Progenitor Cell Sources to Generate Reticulocytes for Plasmodium vivax Culture
Investigators compared the production of reticulocytes using an established in vitro culture system from three different sources of hematopoietic stem/progenitor cells, i.e. umbilical cord blood, bone marrow and adult peripheral blood. [PLoS One] Full Article
FREE Technical Resource: Atlas of Hematopoietic Colonies from Cord Blood. Request your copy.
PUBLICATIONS (Ranked by impact factor of the journal)
Upfront Allogeneic-Stem Cell Transplantation for Patients with Non-Localized Untreated Peripheral T-Cell Lymphoma: An Intention-to-Treat Analysis from a Single Center
Investigators assessed the feasibility and toxicity of upfront allogeneic stem cell transplantation (allo-SCT). 49 newly diagnosed peripheral T-cell lymphoma patients were scheduled to receive upfront allo-SCT. [Ann Oncol] Abstract

Phase I/II Study of Nilotinib Prophylaxis after Allogeneic Stem Cell Transplantation in Patients with Advanced Chronic Myeloid Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Twenty-two patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia underwent stem cell transplantation with human leukocyte antigen-matched siblings, unrelated donors, or alternative donors. [Cancer] Abstract

The Role of Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) were performed in 298 and 122 patients, respectively. For autologous HSCT, overall survival at three years (3yOS) was 70%, and sex, age, disease status, and performance status (PS) at HSCT were prognostic factors. For allogeneic HSCT, 3yOS was 43%, and sex and PS at HSCT were prognostic factors. [Am J Hematol] Abstract

Biological Parameters Influencing the Human Umbilical Cord-Derived Mesenchymal Stem Cells’ Response to Retinoic Acid
Using MTT assay and EB/AO staining as well as TUNEL assay scientists show that retinoic acid (RA) in a concentration-dependent manner induces apoptosis through upregulating Caspase expression and increasing Bax/Bcl2 ratio. Moreover, different biological parameters such as initial time seeding, cell density, passage number and duration of RA treatment play a major role in human umbilical cord-derived mesenchymal stem cells cytotoxic response to this agent. [Biofactors] Abstract

Hematopoietic Stem Cell Transplantation for X-Linked Thrombocytopenia with Mutations in the WAS Gene
To answer the question whether hematopoietic stem cell transplantation (HSCT) offers a viable therapeutic option in X-linked thrombocytopenia (XLT), researchers retrospectively investigated the outcome of HSCT in a cohort of 24 XLT patients who received HSCT at 14 transplant centers in the United States, Italy, Germany, Canada, and Japan. [J Clin Immunol] Abstract

Successful Treatment of Metastatic Rhabdomyosarcoma with Radiochemotherapy and Allogeneic Hematopoietic Stem Cell Transplantation
Researchers report a case of a 21-year-old man with alveolar rhabdomyosarcoma primarily in the right hand with lymph node, lung, bone and bone marrow metastases. Complete remission was achieved after intensive chemotherapy and radiotherapy of the primary and metastatic sites, followed by allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning from a single HLA-DR locus-mismatched mother. [Jpn J Clin Oncol] Abstract

Fetal Heart Extract Facilitates the Differentiation of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells into Heart Muscle Precursor Cells
Investigators aimed to improve the efficacy of differentiation of umbilical cord blood-derived mesenchymal stem cells into cardiomyocytes by combining 5-azacytidine with mouse fetal heart extract in the induction medium. [Cytotechnology] Abstract

FREE Technical Resource: Atlas of Hematopoietic Colonies from Cord Blood. Request your copy.
Current View on Osteogenic Differentiation Potential of Mesenchymal Stromal Cells Derived from Placental Tissues
The applications of three-dimensional environments in vitro and in vivo, such as non-synthetic, polymer-based, and ceramic scaffolds, are discussed, along with results obtained from pre-clinical studies of placental mesenchymal stromal cells for the regeneration of bone defects and treatment of bone-related diseases. [Stem Cell Rev] Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the cord blood research field.
New Autism Study Safety Data to Be Presented at the Translational Neuroscience Cell Symposium
Cord Blood Registry® announced that Dr. Michael G. Chez will present data from the first ever FDA-registered study on the safety of autologous umbilical cord blood stem cells in treating autism. [Press release from Cord Blood Registry® discussing research presented at the Translational Neuroscience: Bridging the Gap Between Basic Research Discoveries and Clinical Applications Cell Symposium, Arlington] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.
Cord Blood Registry Sponsors 2014 World Stem Cell Summit
Cord Blood Registry® announces that the company is a platinum sponsor of the 10th Annual World Stem Cell Summit, the largest global meeting of stem cell science and regenerative medicine stakeholders. [Cord Blood Registry®] Press Release

GlycoMimetics Announces Positive Top-Line Results from Phase I Study of GMI-1271 in Healthy Volunteers
GlycoMimetics, Inc. announced that healthy volunteers in a Phase I clinical study of GMI-1271 tolerated the drug candidate well, and that the pharmacokinetics for the drug candidate were as predicted based on preclinical data. Based on these data, GlycoMimetics is planning a Phase I/II trial of GMI-1271 as an adjunct to standard chemotherapy in patients with acute myeloid leukemia. [GlycoMimetics, Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Mayo Clinic Hematology Review
January 24, 2015
Minneapolis, United States

Visit our events page to see a complete list of events in the cord blood community.
NEW PhD Student – Department of Hematopoiesis (Sanquin)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Fellow – Stem Cell Biology Gene Expression and Regulation (The University of Texas Medical School at Houston)

Postdoctoral Fellow – Molecular Mechanisms Regulating Human Hematopoietic Specification (Washington University School of Medicine)

Postdoctoral Position – NK Cell and Leukemia Research (Children’s Hospital Los Angeles)

Quality Improvement Coordinator – Regenerative Medicine (The University of Texas Health Science Center at Houston)

Postdoctoral Position – Molecular Mechanisms of Hematopoiesis and Blood Disorders (St. Jude Children’s Research Hospital)

Cord Tissue Processing Technician (Cord Blood Registry)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us